{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:03:48Z","timestamp":1792098228360,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11864-016-0434-0","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T03:08:18Z","timestamp":1474254498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Cutaneous Complications of Targeted Melanoma Therapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Emily","family":"de Golian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Swetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvina B.","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"issue":"2","key":"434_CR1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejcsup.2013.07.011","volume":"11","author":"SM Goldinger","year":"2013","unstructured":"Goldinger SM, Murer C, Stieger P, Dummer R. Targeted therapy in melanoma\u2014the role of BRAF, RAS and KIT mutations. EJC Suppl. 2013;11(2):92\u20136.","journal-title":"EJC Suppl"},{"issue":"3","key":"434_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1758834015572284","volume":"7","author":"KF Grossman","year":"2015","unstructured":"Grossman KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol. 2015;7(3):181\u201391.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"434_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314\u201322.","journal-title":"Oncologist"},{"issue":"10","key":"434_CR4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","volume":"151","author":"G Carlos","year":"2015","unstructured":"Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103\u20139. A retrospective cohort study with detailed incidence of cutaneous toxicities comparing vemurafenib to dabrafenib and BRAF inhibitor monotherapy to BRAF inhibitor\/MEK inhibitor combination therapy.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"434_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"434_CR6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/DAD.0b013e3182858142","volume":"36","author":"R Anforth","year":"2014","unstructured":"Anforth R, Fernandez-Penas P. BRAF inhibitor induced verrucal keratosis. Am J Dermatopathol. 2014;36(2):192.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"434_CR7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1755-148X.2012.01031.x","volume":"25","author":"R Anforth","year":"2012","unstructured":"Anforth R, Tembe V, Blumetti T, Fernandez-Pe\u00f1as P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012;25(5):569\u201372.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1 Suppl 1","key":"434_CR8","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaad.2012.10.001","volume":"68","author":"DS Rigel","year":"2013","unstructured":"Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S20\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"434_CR9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"RM Anforth","year":"2012","unstructured":"Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153\u201360.","journal-title":"Br J Dermatol"},{"issue":"1","key":"434_CR10","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","volume":"14","author":"R Anforth","year":"2013","unstructured":"Anforth R, Fernandez-Pe\u00f1as P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11\u20138.","journal-title":"Lancet Oncol"},{"issue":"1","key":"434_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13200","volume":"172","author":"R Anforth","year":"2015","unstructured":"Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Pe\u00f1as P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172(1):239\u201343. This study emphasizes the need for long-term monitoring in patients treated with BRAF inhibitors due to the continued development of cutaneous adverse events, including cutaneous squamous cell carcinomas, after 52 weeks of therapy.","journal-title":"Br J Dermatol"},{"issue":"1","key":"434_CR12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamadermatol.2014.2455","volume":"151","author":"E Lilly","year":"2015","unstructured":"Lilly E, Burke M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib. JAMA Dermatol. 2015;151(1):102\u20133.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"434_CR13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"434_CR14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","volume":"24","author":"I Amitay-Laish","year":"2011","unstructured":"Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24(4):386\u201395.","journal-title":"Dermatol Ther"},{"issue":"19","key":"434_CR15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375\u201383.","journal-title":"J Clin Oncol"},{"issue":"3","key":"434_CR16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.06.006","volume":"73","author":"MC Mochel","year":"2015","unstructured":"Mochel MC, Hammond MR, Frederick DT, et al. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: a study of 19 lesions from 10 patients. J Am Acad Dermatol. 2015;73(3):491\u20139.e2. Histopathologic and immunohistochemical evaluation of excised nevi during BRAFi monotherapy, showing that new\/changing nevi are BRAF wild-type lesions.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"434_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol"},{"key":"434_CR18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"434_CR19","unstructured":"Kwong B. Dermatologic toxicities of melanoma drugs. Presented 23 March 2015 at the American Academy of Dermatology 73rd Annual Meeting. Lecture."},{"issue":"5","key":"434_CR20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","volume":"148","author":"V Huang","year":"2012","unstructured":"Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628\u201333.","journal-title":"Arch Dermatol"},{"issue":"1","key":"434_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jdv.12449","volume":"29","author":"L Vanneste","year":"2015","unstructured":"Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol. 2015;29(1):61\u20138. Prospective study of twenty patients detailing extent of cutaneous toxicity and accompanied by excellent clinical photographs.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"434_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"434_CR23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","volume":"71","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M, Choudhry A, Vujic I, et al. Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71(6):1102\u20131109.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"434_CR24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamadermatol.2014.838","volume":"150","author":"FW Chen","year":"2014","unstructured":"Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014;150(11):1209\u201312.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"434_CR25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamadermatol.2014.3207","volume":"151","author":"U Patel","year":"2015","unstructured":"Patel U, Cornelius L, Anadkat MJ. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients. JAMA Dermatol. 2015;151(1):78\u201381.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"434_CR26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","volume":"29","author":"Y Balagula","year":"2011","unstructured":"Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 2011;29(5):1114\u201321.","journal-title":"Invest New Drugs"},{"issue":"1","key":"434_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12788\/j.sder.0061","volume":"33","author":"JN Choi","year":"2014","unstructured":"Choi JN. Dermatologic adverse events to chemotherapeutic agents, part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg. 2014;33(1):40\u20138.","journal-title":"Semin Cutan Med Surg"},{"issue":"12","key":"434_CR28","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1172\/JCI70895","volume":"123","author":"T Leung","year":"2013","unstructured":"Leung T, Zhang LF, Wang J, et al. Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice. J Clin Invest. 2013;123(12):5361\u201370.","journal-title":"J Clin Invest"},{"issue":"13","key":"434_CR29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389\u201398.","journal-title":"Lancet Oncol"},{"issue":"8","key":"434_CR30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"434_CR31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","volume":"69","author":"CJ Ensslin","year":"2013","unstructured":"Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708\u201320. Detailed analysis of pruritus, an important but often overlooked symptom affecting patient quality of life during cancer therapy.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"434_CR32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","volume":"71","author":"ME Lacouture","year":"2014","unstructured":"Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161\u20139. Treatment algorithm for rash associated with ipilimumab.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"434_CR33","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","volume":"13","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020\u20134. A novel and effective therapy for pruritus associated with chemotherapy.","journal-title":"Lancet Oncol"},{"issue":"28","key":"434_CR34","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193\u20138.","journal-title":"J Clin Oncol"},{"issue":"22 Pt 1","key":"434_CR35","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681\u20138.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"434_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"S Sheik Ali","year":"2015","unstructured":"Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015;151(2):195\u20139.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"434_CR37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","volume":"22","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265\u20138.","journal-title":"Trends Immunol"},{"issue":"26","key":"434_CR38","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"434_CR39","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","volume":"152","author":"MB Totonchy","year":"2016","unstructured":"Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 2016;152(5):590\u20132.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"434_CR40","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206\u201312. The development of cutaneous adverse events in patients undergoing therapy with pembrolizumab may portend a favorable prognosis, although further studies are necessary.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"434_CR41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in 3 patients with metastatic melanoma treated with anti-PD1 therapy. Cancer Immunol Res. 2015;3(1):18\u201322.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"434_CR42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","volume":"43","author":"KB Schaberg","year":"2016","unstructured":"Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339\u201346.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"434_CR43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45\u201351.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"434_CR44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","volume":"25","author":"G Carlos","year":"2015","unstructured":"Carlos G, Anforth R, Chou S, Clements A, Fernandez-Pe\u00f1as P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25(3):265\u20138.","journal-title":"Melanoma Res"},{"issue":"5","key":"434_CR45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","volume":"4","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383\u20139.","journal-title":"Cancer Immunol Res"}],"updated-by":[{"DOI":"10.1007\/s11864-016-0440-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:00:00Z","timestamp":1478304000000}}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-016-0434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-016-0434-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-016-0434-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:06:20Z","timestamp":1498345580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-016-0434-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s11864-016-0434-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11864-016-0440-2","asserted-by":"object"}]},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]},"article-number":"57"}}